🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

4,196 results for “GE” Clear

  1. BGB DXP593

    BeiGene

    Covid19

    phase 1 small molecule completed

    1 trial

  2. BI 1015550, NERANDOMILAST

    Boehringer Ingelheim

    Healthy volunteer trial

    phase 1 small molecule active

    1 trial

  3. BI 3011441

    Boehringer Ingelheim

    Solid Tumors, KRAS Mutation

    phase 1 small molecule completed

    1 trial

  4. BI 695502

    Boehringer Ingelheim

    Healthy

    phase 1 small molecule completed

    1 trial

  5. BI 765063

    Boehringer Ingelheim

    Head and Neck Squamous Cell Carcinoma (HNSCC)

    phase 1 small molecule active

    1 trial

  6. BI 905711

    Boehringer Ingelheim

    Gastrointestinal Neoplasms

    phase 1 small molecule completed

    1 trial

  7. BIIB115

    Biogen

    Healthy Volunteer

    phase 1 small molecule active

    1 trial

  8. BPX-601

    Regeneron UK Limited

    Metastatic Castration-resistant Prostate Cancer

    phase 1 mab terminated

    1 trial

  9. BPX-601

    Regeneron UK Limited

    Prostate Cancer

    phase 1 gene therapy active

    1 trial

  10. BZ019

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Large B-cell Lymphoma

    phase 1 mab active

    1 trial

  11. Beamion LUNG-1: A study to test different doses of zongertinib in people with different types of advanced cancer (solid tumours with changes in the HER2 gene)

    Boehringer Ingelheim

    Solid tumours with HER2 aberrations, Non-small cell lung cancer

    phase 1 other active

    1 trial

  12. Bexarotene (Targretin®)

    LIGAND PHARMACEUTICALS INC

    Advanced, Malignant Aerodigestive Tract Tumor (Lung, Head and Neck and Esophagus)

    phase 1 small molecule completed

    1 trial

  13. BiiB115 placebo is a sterile liquid for injection. the formulation composition of the placebo is identical to that of BIIB115 drug product minus the active ingredient, BIIB115

    Biogen

    Spinal muscular atrophy

    phase 1 small molecule active

    1 trial

  14. Bimzelx 320 mg solution for injection in pre-filled pen, Bimzelx 160 mg solution for injection in pre-filled syringe, Bimzelx 160 mg solution for injection in pre-filled syringe, Bimzelx 160 mg solution for injection in pre-filled pen, Bimzelx 160 mg solution for injection in pre-filled pen, Bimzelx 160 mg solution for injection in pre-filled syringe, Bimzelx 320 mg solution for injection in pre-filled syringe, Bimzelx 160 mg solution for injection in pre-filled pen, Bimzelx 160 mg solution for injection in

    Lacuna Pharma Pty Ltd

    Hidradenitis suppurativa, Axial spondyloarthritis, Moderate to Severe Plaque Psoriasis, Psoriatic arthritis

    phase 1 small molecule active

    1 trial

  15. Binimetinib

    Takeda

    ALK Gene Rearrangement

    phase 1 small molecule terminated

    1 trial

  16. Bioequivalence of Etonogestrel 68 mg Implant in Healthy Pre-Menopausal, Non-Pregnant Female Participants.

    Laboratorios Tillomed Spain S.L.U

    No medical condition

    phase 1 other active

    1 trial

  17. Bioequivalence of Etonogestrel 68 mg Implant in Healthy Pre-Menopausal, Non-Pregnant Female Participants.

    Laboratorios Tillomed Spain S.L.U

    No medical condition.

    phase 1 other active

    1 trial

  18. Bioequivalence of Mirabegron 50 mg Prolonged-Release Tablets in Healthy Participants Under Fasting Conditions.

    Laboratorios Tillomed Spain S.L.U

    No medical condition.

    phase 1 other active

    1 trial

  19. Bioequivalence of Mirabegron 50 mg Prolonged-Release Tablets in Healthy Participants Under Fed Conditions.

    Laboratorios Tillomed Spain S.L.U

    No medical condition.

    phase 1 other active

    1 trial

  20. Bioequivalence of One Tablet of Gliclazide MR 120 mg (S005190) and Two Tablets of Gliclazide MR 60 mg (Diamicron® MR) in Healthy Participants under Fasting Conditions.

    The George Institute

    No medical condition.

    phase 1 other active

    1 trial

  21. Bioequivalence of One Tablet of Gliclazide MR 120 mg (S005190) and Two Tablets of Gliclazide MR 60 mg (Diamicron® MR) in Healthy Participants under Fed Conditions.

    The George Institute

    No medical condition.

    phase 1 other active

    1 trial

  22. Bioequivalence of One Tablet of Gliclazide MR 90 mg (S005190) and One and a Half Tablets of Gliclazide MR 60 mg (Diamicron® MR) in Healthy Participants under Fed Conditions.

    The George Institute

    No medical condition.

    phase 1 other active

    1 trial

  23. Bioequivalence of Testosterone Transdermal Gel in Healthy Female Participants.

    Laboratorios Tillomed Spain S.L.U

    No medical conditions.

    phase 1 other active

    1 trial

  24. Bioequivalence study of GP-IMP-001 with regards to reference product

    Lacuna Pharma Pty Ltd

    healthy volunteers

    phase 1 other active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources